A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.
A startup that utilizes marine photosynthetic bacteria to fix CO2 and nitrogen, producing agricultural fertilizers, aquaculture feed, and protein materials. It achieves greenhouse gas reduction and resource circulation, promoting sustainable local production for local consumption.
A startup utilizing digital holography technology to measure the minute three-dimensional shapes of objects with high precision and speed. It contributes to improving quality control for semiconductors and space equipment, enabling efficient precision measurement through non-contact and non-destructive methods.
A Kyoto University-spinoff startup has developed technology that analyzes forest trees down to their species, height, and carbon content using drones and AI. It supports carbon credit creation and monitoring based on forest data.
Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.